Emmaus Life Sciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Emmaus Life Sciences Inc (EMMAW) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Emmaus Life Sciences Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 12M vs 81,639M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+26.6% annualized vs trailing 12 months), vs decelerating (-10.5%) for its tracked peer group.
- Growth: Emmaus Life Sciences Inc generated 24.6% revenue growth year over year in Q4 2025, vs -6.9% for its competitors combined.
- Profitability: Its -50.7% net margin compares with 0.5% for the peer group.
- Peer revenue share: Emmaus Life Sciences Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.37M compares with $0.87M for the peer group (0.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
EMMAW Sales vs. its Competitors, Q4 2025
Emmaus Life Sciences Inc reported revenue growth of 24.62 % year on year in Q4 2025, above its competitors' combined revenue change of -6.86 %.
With a net margin of -50.65 %, Emmaus Life Sciences Inc reported lower profitability than its competitors (0.52 %).
Emmaus Life Sciences Inc generated 0.02 % of the combined sales of its peer group, up from 0.02 % a year earlier.
API endpoints for this dataset
Emmaus Life Sciences Inc vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Emmaus Life Sciences Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Emmaus Life Sciences Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Emmaus Life Sciences Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Emmaus Life Sciences Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs 24.6% for Emmaus Life Sciences Inc. Emmaus Life Sciences Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Emmaus Life Sciences Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Emmaus Life Sciences Inc | No | No | No | No |
| Competitors combined (42) | ||||
| High-Confidence Competitors (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
EMMAW Stock Performance relative to its Competitors
EMMAW Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Centessa Pharmaceuticals Plc | 282.9% | Outperformed |
| 2 | Avadel Pharmaceuticals Plc | 282.9% | Outperformed |
| 3 | Amicus Therapeutics inc | 282.9% | Outperformed |
| 4 | Viatris Inc | 282.9% | Outperformed |
| 5 | Clover Health Investments Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Emmaus Life Sciences Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Emmaus Life Sciences Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Emmaus Life Sciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Emmaus Life Sciences Inc |
3.59 | 12.17 |
 Amgen Inc |
254,015.58 | 38,903.00 |
 Teva Pharmaceutical Industries Limited |
50,159.20 | 14,020.00 |
 Insmed Inc |
26,142.98 | 1,479.04 |
 Viatris Inc |
24,254.81 | 14,737.30 |
 Biomarin Pharmaceutical Inc |
11,059.80 | 3,655.13 |
| SUBTOTAL | 419,132.48 | 82,063.09 |
Sign in to see all competitors of Emmaus Life Sciences Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Emmaus Life Sciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Emmaus Life Sciences Inc's Competitors Named by the Company
Competitive relationships identified from Emmaus Life Sciences Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Agios Pharmaceuticals Inc | Company report | 85% |
| National Institutes of Health | Company report | 85% |
Company report basis, confidence, active dates and source counts for Emmaus Life Sciences Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Emmaus Life Sciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Insmed Inc | Reportable 100.00 % |
| Viatris Inc | Developed Markets 59.34 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Emmaus Life Sciences Inc .
Emmaus Life Sciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Emmaus Life Sciences Inc | 4 | 368,667 | -217,091 |
| Amgen Inc | 254,016 | 2,992,538 | 722,385 |
| Teva Pharmaceutical Industries Limited | 50,159 | 412,960 | 14,963 |
| Insmed Inc | 26,143 | 888,846 | -363,948 |
| Viatris Inc | 24,255 | 491,243 | -13,690 |
| Biomarin Pharmaceutical Inc | 11,060 | 1,134,780 | -5,934 |
| PEERS TOTAL | 419,129 | 870,068 | 62,310 |
Sign in to see all peers for Emmaus Life Sciences Inc .
Emmaus Life Sciences Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Insmed Inc | United States 90.31 % |
| Ultragenyx Pharmaceutical Inc | North America 52.02 % |
| Therapeuticsmd Inc | Non Us 66.30 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Emmaus Life Sciences Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 491 companies in Emmaus Life Sciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.Emmaus Life Sciences Inc ranks #0 of 491 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 988, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,280,038 | 23.96 % |
| 2 | Johnson and Johnson | 685,131 | 12.82 % |
| 3 | Abbvie Inc | 520,479 | 9.74 % |
| 4 | Merck and Co Inc | 365,659 | 6.84 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Emmaus Life Sciences Inc | 2 | 0.00 % |
Market cap and industry share for the rest of Emmaus Life Sciences Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2022-03-14.
Emmaus Life Sciences Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (446 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 94.10 % | 37.92 % (avg) | +56.2 pp |
| Operating Margin | -9.43 % | industry median | -14.6 pp |
| EBITDA Margin | -75.25 % | -6.30 % (avg) | -68.9 pp |
| Capital Intensity (Capex / Revenue) | - | 7.51 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Emmaus Life Sciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 500.00 % | 500.00 % | 45.09 % | -37.57 % | -10.77 % | 59.08 % | -43.76 % | -39.43 % |
| Operating Margin | -643.48 % | -19.83 % | 25.93 % | -29.73 % | -35.81 % | 12.10 % | -11.51 % | -9.43 % |
| Return on Invested Capital | -225.79 % | -84.78 % | 31.24 % | - | - | - | - | - |
| P/E | - | - | 0.1x | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Emmaus Life Sciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 988 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Emmaus Life Sciences Inc's dedicated Suppliers and Customers pages, not here.
Emmaus Life Sciences Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Emmaus Life Sciences Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Emmaus Life Sciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+26.6% annualized vs trailing 12 months).
Weaknesses
- Operating margin 14.6 points below the industry median.
Opportunities
- A meaningful share of competitors (45.20 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-10.5% annualized).
Methodology: see Methodology: SWOT Analysis.
Emmaus Life Sciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Emmaus Life Sciences Inc | 0.02 | 0.10 | - |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Teva Pharmaceutical Industries Limited | 0.26 | 0.96 | 2.09 |
| Insmed Inc | 0.94 | 3.11 | 0.75 |
| Viatris Inc | 0.18 | 1.47 | 0.96 |
| Biomarin Pharmaceutical Inc | 1.07 | 3.41 | 0.47 |
Sign in to see all peers for Emmaus Life Sciences Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Emmaus Life Sciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Emmaus Life Sciences Inc | Q4 2025 | -29.7 % | - |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Teva Pharmaceutical Industries Limited | Q3 2026 | -1.9 % | -46.3 % |
| Insmed Inc | Q3 2026 | +330.0 % | - |
| Viatris Inc | Q2 2026 | +4.9 % | - |
| Biomarin Pharmaceutical Inc | Q3 2026 | +32.0 % | - |
| PEERS TOTAL | +10.2 % | +18.4 % |
Sign in to see all peers for Emmaus Life Sciences Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Emmaus Life Sciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Emmaus Life Sciences Inc | Q4 2025 | -40.4 % | - |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Teva Pharmaceutical Industries Limited | Q3 2026 | -10.2 % | +200.0 % |
| Insmed Inc | Q3 2026 | +166.4 % | +132.6 % |
| Viatris Inc | Q2 2026 | +2.3 % | -0.2 % |
| Biomarin Pharmaceutical Inc | Q3 2026 | +46.6 % | -18.9 % |
Sign in to see all peers for Emmaus Life Sciences Inc .
Emmaus Life Sciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Emmaus Life Sciences Inc | - | - | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Teva Pharmaceutical Industries Limited | 1.26% | 1.96% | 6.37% |
| Insmed Inc | - | - | - |
| Viatris Inc | - | - | - |
| Biomarin Pharmaceutical Inc | - | - | - |
Sign in to see all peers for Emmaus Life Sciences Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Emmaus Life Sciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Emmaus Life Sciences Inc | - | 0.29 |
| Amgen Inc | 26.97 | 6.53 |
| Teva Pharmaceutical Industries Limited | 56.79 | 3.58 |
| Insmed Inc | - | 17.68 |
| Viatris Inc | - | 1.65 |
| Biomarin Pharmaceutical Inc | - | 3.03 |
| PEERS AVERAGE | 71.42 | 5.11 |
Sign in to see all peers for Emmaus Life Sciences Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.